Skip to main
FATE
FATE logo

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics (FATE) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Fate Therapeutics Inc. has demonstrated promising early results for its FT819 cell therapy in patients with lupus, showcasing significant improvements in clinical measures such as SLEDAI-2K, including reductions from baseline scores and instances of drug-free remission beyond one year. The positive data presented at both the EULAR and ACR meetings indicates that FT819 could offer a durable and effective treatment option for heavily pretreated patients, emphasizing its potential as an allogeneic CAR-T therapy in the lupus market. With encouraging clinical outcomes and a robust development pipeline focused on immunotherapies, Fate Therapeutics's stock outlook remains favorable as it continues to further its innovative therapeutic advancements.

Bears say

Fate Therapeutics Inc faces significant risks that contribute to a negative outlook, including the uncertainty surrounding the clinical efficacy of its lead product, FT819, particularly in comparison to existing CAR-T therapies. The data from early trials suggest only transient effects with limited patient follow-up, making it difficult to assess the long-term clinical benefits of FT819. Additionally, potential partnership challenges, regulatory hurdles, and medium-term dilution risks further complicate the company’s financial stability and future growth prospects.

Fate Therapeutics (FATE) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fate Therapeutics (FATE) Forecast

Analysts have given Fate Therapeutics (FATE) a Buy based on their latest research and market trends.

According to 6 analysts, Fate Therapeutics (FATE) has a Buy consensus rating as of Nov 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fate Therapeutics (FATE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.